Premium
Immunoreactivity for cadherins, HGF/SF, met, and erbB‐2 in pleural malignant mesotheliomas
Author(s) -
Thirkettle I,
Harvey P,
Hasleton P S,
Ball R Y,
Warn R M
Publication year - 2000
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1046/j.1365-2559.2000.00888.x
Subject(s) - hepatocyte growth factor , mesothelioma , immunoperoxidase , pathology , immunohistochemistry , medicine , cadherin , receptor tyrosine kinase , pleural disease , antibody , tyrosine kinase , c met , cancer research , receptor , monoclonal antibody , biology , lung , respiratory disease , cell , immunology , genetics
Aims To assess the immunoreactivity of malignant mesotheliomas for N‐ and E‐cadherins, hepatocyte growth factor/scatter factor (HGF/SF) and the tyrosine kinase receptors, met and erbB‐2. Methods and results Pleural malignant mesotheliomas were stained using a standard indirect immunoperoxidase method applied to paraffin sections. Malignant mesotheliomas were immunoreactive for N‐cadherin (26/29; 90%), met (29/29; 100%) and erbB‐2 (28/29; 97%). Focal immunoreactivity was present for E‐cadherin in epithelioid or mixed tumours (14/25; 56%), and for HGF/SF (9/24; 38%). Conclusions Expression of N‐cadherin supports the diagnosis of malignant mesothelioma and use of appropriate antibodies would be a useful addition to a diagnostic antibody panel. Focal staining for E‐cadherin does not exclude mesothelioma. Signalling pathways mediated via met and erbB‐2 may play a role in the growth and spread of malignant mesotheliomas.